M edical device company Globus Medical (NYSE:GMED) in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company’s series of product launches aid growth. The stock sports a Zacks ...

Globus Medical seems to be reverting to form, reporting a big jump in operating profit and profit margin for Q1, 2025. Here ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Globus Medical reports quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 57 cents by 26.32%. Quarterly sales come in at $606.67 million which beat the analyst ...

Other than some upbeat news on new products being introduced, it has been rather quiet on the corporate front, with Globus Medical posting only the regular quarterly results. Second quarter sales ...

Although the company reported solid sales for 3Q23 ... seems to have led Lichtman to retain a Hold rating for Globus Medical. According to TipRanks, Lichtman is a 5-star analyst with an average ...